Last10K.com

Aaipharma Inc (1013243) SEC Filing 10-Q Quarterly report for the period ending Thursday, June 30, 2005

Aaipharma Inc

HISTORY TOOLS
CIK: 1013243
 

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 3, 2005
aaiPharma Inc.
(Exact Name of Registrant as Specified in its Charter)
         
Delaware   0-21185   04-2687849
         
(State or Other Jurisdiction   (Commission File Number)   (I.R.S. Employer
of Incorporation)       Identification No.)
2320 Scientific Park Drive
Wilmington, North Carolina 28405
 
(Address of Principal Executive Offices)
(Zip Code)
(910) 254-7000
 
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
 
(Former name or former address, if changed from last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o      Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c))

 

The following information was filed by Aaipharma Inc on Tuesday, August 9, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aaipharma Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aaipharma Inc.

Continue

Assess how Aaipharma Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aaipharma Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2005 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
CIK: 1013243
Form Type: 10-Q Quarterly Report
Accession Number: 0000950144-05-011526
Submitted to the SEC: Wed Nov 09 2005 4:41:57 PM EST
Accepted by the SEC: Wed Nov 09 2005
Period: Thursday, June 30, 2005
Industry: Testing Laboratories

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1013243/0000950144-05-011526.htm